476192-42-4Relevant academic research and scientific papers
Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective α-sulfone hydroxamates
Kolodziej, Stephen A.,Hockerman, Susan L.,Boehm, Terri L.,Carroll, Jeffery N.,Decrescenzo, Gary A.,McDonald, Joseph J.,Mischke, Debbie A.,Munie, Grace E.,Fletcher, Theresa R.,Rico, Joseph G.,Stehle, Nathan W.,Swearingen, Craig,Becker, Daniel P.
scheme or table, p. 3557 - 3560 (2010/09/04)
A series of phenyl piperidine α-sulfone hydroxamate derivatives has been prepared utilizing a combination of solution-phase and resin-bound library technologies to afford compounds that are potent and highly selective for MMP-13, are dual-sparing of MMP-1
Aromatic sulfone hydroxamates and their use as protease inhibitors
-
Page 148, (2010/02/05)
This invention is directed to aromatic sulfone hydroxamates (also known as “aromatic sulfone hydroxamic acids”) and salts thereof that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to a prevention or treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP and/or aggrecanase activity.
